S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
$130 trillion revolution in this cup? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
$130 trillion revolution in this cup? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
$130 trillion revolution in this cup? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
S&P 500   3,678.43
DOW   29,490.89
QQQ   273.53
Being a Human Magnet Is Key to Your Company's Success. Here's What That Means.
$130 trillion revolution in this cup? (Ad)
Near-Term Headwinds Send Nike To The Bargain Basement 
Sweden sends special diving vessel to area of pipeline leaks
$130 trillion revolution in this cup? (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Fraud, scam cases increasing on Zelle, Senate report finds
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
UK scraps tax cut for wealthy that sparked market turmoil
Supreme Court won't take up MyPillow head's defamation case
NASDAQ:MESO

Mesoblast - MESO Stock Forecast, Price & News

$2.73
+0.19 (+7.48%)
(As of 10/3/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.61
$2.88
50-Day Range
$2.55
$3.49
52-Week Range
$2.14
$7.28
Volume
213,941 shs
Average Volume
74,466 shs
Market Capitalization
$402.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Mesoblast MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
74.0% Upside
$4.75 Price Target
Short Interest
Healthy
0.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Mesoblast in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.53) to ($0.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

682nd out of 1,093 stocks

Biological Products, Except Diagnostic Industry

112th out of 171 stocks

MESO stock logo

About Mesoblast (NASDAQ:MESO) Stock

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Stock News Headlines

Mesoblast Limited
Mesoblast Earnings beat, Revenue misses In Q4
China Fears Drag Asian Stocks Lower - Nasdaq
Form F-3 MESOBLAST LTD - StreetInsider.com
Jane Bell Joins Mesoblast Board - GlobeNewswire
Jane Bell Joins Mesoblast Board
Form 6-K MESOBLAST LTD For: Aug 15 - StreetInsider.com
Form 6-K MESOBLAST LTD For: Aug 05 - StreetInsider.com
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Company Calendar

Last Earnings
8/30/2022
Today
10/04/2022
Next Earnings (Estimated)
11/22/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+74.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-91,350,000.00
Net Margins
-894.33%
Pretax Margin
-896.67%

Debt

Sales & Book Value

Annual Sales
$10.21 million
Book Value
$3.82 per share

Miscellaneous

Free Float
119,708,000
Market Cap
$402.47 million
Optionable
Optionable
Beta
3.13

Key Executives

  • Dr. Silviu Itescu FACP (Age 65)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
    Comp: $943.98k
  • Dr. Eric A. Rose M.D. (Age 71)
    Chief Medical Officer & Exec. Director
    Comp: $379.45k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Fin. Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A. (Age 58)
    M.S., Chief Operating Officer
  • Mr. Peter T. Howard B.Sc. (Age 54)
    L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec.
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster M.B.A. (Age 45)
    MS, BSc, MBA, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., Bsc, MMS, MBA, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Sec.













MESO Stock - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings
or view top-rated stocks.

What is Mesoblast's stock price forecast for 2022?

2 brokers have issued 12 month price objectives for Mesoblast's shares. Their MESO share price forecasts range from $2.50 to $7.00. On average, they expect the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 74.0% from the stock's current price.
View analysts price targets for MESO
or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2022?

Mesoblast's stock was trading at $4.80 at the beginning of 2022. Since then, MESO stock has decreased by 43.1% and is now trading at $2.73.
View the best growth stocks for 2022 here
.

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 22nd 2022.
View our MESO earnings forecast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) issued its quarterly earnings data on Tuesday, August, 30th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.07. Mesoblast had a negative trailing twelve-month return on equity of 17.32% and a negative net margin of 894.33%.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $2.73.

How much money does Mesoblast make?

Mesoblast (NASDAQ:MESO) has a market capitalization of $402.47 million and generates $10.21 million in revenue each year. The company earns $-91,350,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030.

This page (NASDAQ:MESO) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.